[Estrogens and selective estrogen receptor modulators in the treatment of osteoporosis].
Estrogen deficiency is the major determinant of bone loss, not only in the first years postmenopause, but also throughout the entire life and in the elderly. Major progress in the knowledge of cellular actions of estrogens has been made leading to a better understanding of the underlying mechanisms of different estrogen-deficiency related diseases such as osteoporosis, atherosclerosis and also maybe cerebral aging. Estrogen replacement therapy remains the first choice treatment in the prevention of postmenopausal osteoporosis, but the continuous aging process of the female population raises the question of a better strategy of action in a more efficient prevention of hip fractures. Moreover, the potential gynecological effects of estrogens are likely to limit their indications or long-term use. The development of new compounds, called SERMs (selective estrogen receptor modulators), with both agonist and antagonist estrogen actions, in particular with no negative effects on the uterus and the breast opens new therapeutical insights into the prevention of postmenopausal osteoporosis.
Ribot
C
C
Unité Ménopause et Maladies Métabolique, Service d'Endocrinologie, CHU Rangueil, 31403 Toulouse Cedex 4.
Tremollieres
F
F
Pouilles
J M
JM
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001842:Bone and Bones / Q000187:drug effects; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators